Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.56 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | GLS | O94925 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19074543 | 1.00 | POLB (0.66) | POLBROCK2ROCK1BAZ1AMEN1 | |
| Hydrochloric Acid SCHEMBL8010089 | 0.98 | POLB (0.63) | POLBROCK2ROCK1BAZ1AMEN1 | |
| Hydrochloric Acid SCHEMBL8010083 | 0.98 | POLB (0.63) | POLBROCK2ROCK1BAZ1AMEN1 | |
| Dimethylamine SCHEMBL6726772 | 0.94 | POLB (0.59) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL23611208 | 0.91 | ROCK2 (0.56) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL23611205 | 0.91 | ROCK2 (0.56) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL16943502 | 0.88 | POLB (0.51) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL20491035 | 0.88 | POLB (0.51) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL7680844 | 0.88 | POLB (0.51) | POLBROCK2ROCK1BAZ1AMEN1 | |
| SCHEMBL23611109 | 0.88 | KMT2A (0.56) | POLBROCK2ROCK1BAZ1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | POLB 4182/4885ROCK2 4063/4885ROCK1 3294/4885 |
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | POLB 4412/4885ROCK2 4242/4885ROCK1 3247/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | POLB 922/4885ROCK2 4583/4885ROCK1 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.